LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

The agreement grants Iksuda access to Legochem Biosciences’ next-generation PBD Prodrug payload and proprietary linker to discover and advance ADCs for difficult-to-treat tumours

Iksuda gains certain rights to LCB’s ADC technology, ConjuALL, including LCB’s tumour-selectively activated payloads as well as its proprietary linker and conjugation platform, to research, develop and commercialize targeted anti-cancer therapeutics. Under the terms of the agreement, Iksuda has the rights to use the LCB technology to develop therapeutics directed to up to three undisclosed targets.

The agreement allows Iksuda to build on its already impressive portfolio of ADC assets and provides more scope to match the best ADC components to create best-in-class drugs according to target antigen and tumour. Through this partnership, Iksuda can leverage LCB’s next-generation linker and payload platform and, through its Team’s expertise and proven capability in ADC development, will advance ADCs to the clinic as quickly as possible.